Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Refractory or Relapsed Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Lethal Congenital Contracture Syndrome 2 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Carboplatin 52pembrolizumab 51Pemetrexed 44Cisplatin 35Paclitaxel 21Nivolumab 20Docetaxel 19durvalumab 17Gemcitabine 14130-nm albumin-bound paclitaxel 14osimertinib 13Cetuximab 12Specimen Handling 11Magnetic Resonance Spectroscopy 11atezolizumab 10amivantamab 8Taxes 7Radiotherapy 7lazertinib 6alectinib 6Ramucirumab 6Radiosurgery 6Observation 6Ipilimumab 6Bevacizumab 6cemiplimab 5Leucovorin 5Fluorouracil 5zimberelimab 4entrectinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Itraconazole × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡